Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 10,869 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 105 Years
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
Conditions
Advanced Solid Tumor, Gynecologic Cancer
Interventions
Lucitanib, Nivolumab
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
Conditions
Esophageal Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Tony Bekaii-Saab
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Terminated No phase listed Observational Accepts healthy volunteers

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

NCT02024243
Conditions
Non-Diabetic Patients, Wound Leg, Chronic Ulcer Leg/Foot
Interventions
Not listed
Lead sponsor
Chandan Sen
Other
Eligibility
30 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Columbus, Ohio
Completed Not applicable Interventional Results available

Respicardia, Inc. Pivotal Trial of the remedē System

NCT01816776
Conditions
Sleep Apnea, Central, Sleep Disordered Breathing, Heart Failure
Interventions
Treatment Group (transvenous stimulation of the phrenic nerve), Control Group (Optimal Medical Therapy)
Device
Lead sponsor
Respicardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Los Angeles, California • Jacksonville, Florida • Downers Grove, Illinois + 19 more
Conditions
Regional Anesthesia Morbidity
Interventions
Electrocardiogram
Diagnostic Test
Lead sponsor
Senthil G. Krishna
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
78
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Conditions
Liver Cancer
Interventions
Brivanib, Placebo, Best Supportive Care
Drug · Other · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
19
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
541
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Conditions
Lipoprotein(a)
Interventions
MK-7262, Enlicitide, Placebo for MK-7262, Placebo for enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Conditions
Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions
Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more
Completed Not applicable Interventional Results available

ICG Use in Angiography for Nasoseptal Flap Harvest

NCT02117310
Conditions
Skull Base Neoplasms
Interventions
indocyanine green
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
80,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Conditions
Lymphoma
Interventions
Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
44
States / cities
Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more